drugset / Trial / NCT04547062
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1 dose escalation study testing the addition of an anti-IL6 (tocilizumab) to standard induction chemotherapy for high-risk AML.
Timeline
- Start
- 2020-12-29
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |